Dicerna Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Dicerna Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Dec 2020 | Lorem |
| Dicerna to welcome CRO pitches for Phase I DCR-undisclosed liver trial in mid-2020, decisions by late 2020, CEO says | 21 Nov 2019 | Shuan Sim |
| Alnylam’s early lumasiran data provides optimism for Phase III primary hyperoxaluria type 1 surrogate endpoint, but clinical outcomes beyond Phase III key for long-term use, experts say | 28 Jun 2019 | Manasi Vaidya |
| Dicerna appoints Premier Research as CRO for Phase II primary hyperoxaluria study of DCR-PHXC, expects open-label extension data by YE, says CEO | 06 May 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer